Abstract

The functions of the Solid Tumor Pharmacology Core are to: A. Perform assays to quantitate drug and drug metabolite concentrations in biological specimens collected from animals and patients as part of preclinical and clinical pharmacokinetic studies within this Program. B. Perform additional special laboratory procedures as required to support the projects included in this Program. C. Perform appropriate biochemical assays (e.g., immunoblot analysis for topoisomerase I, catalytic activity of topoisomerase I) on preclinical and clinical samples to evaluate the activity of anticancer drugs to provide more comprehensive pharmacodynamic analyses. D. Maintain computer databases of data from analyses performed in the Solid Tumor Pharmacology Core, and generate data retrievals and reports as required. E. Analyze pharmacokinetic data obtained from preclinical and clinical pharmacokinetic studies, and fit appropriate pharmacokinetic and pharmacodynamic models to the data, as requested by investigators in this Program.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023099-21
Application #
6101973
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
21
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105

  Publications

Dowless, Michele; Lowery, Caitlin D; Shackleford, Terry et al. (2018) Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. Clin Cancer Res 24:6028-6039
Bishop, Michael W; Advani, Shailesh M; Villarroel, Milena et al. (2018) Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. J Glob Oncol :1-11
Wang, Tingting; Liu, Lingling; Chen, Xuyong et al. (2018) MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis 9:220
Feng, Helin; Tillman, Heather; Wu, Gang et al. (2018) Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget 9:27087-27091
Hu, Dongli; Jablonowski, Carolyn; Cheng, Pei-Hsin et al. (2018) KDM5A Regulates a Translational Program that Controls p53 Protein Expression. iScience 9:84-100
Power-Hays, Alexandra; Friedrich, Paola; Fernandez, Gretchen et al. (2017) Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study. Pediatr Blood Cancer 64:
Brennan, Rachel C; Qaddoumi, Ibrahim; Mao, Shenghua et al. (2017) Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77
Yu, Peter Y; Gardner, Heather L; Roberts, Ryan et al. (2017) Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One 12:e0181885
Yang, Jun; Milasta, Sandra; Hu, Dongli et al. (2017) Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Res 77:4626-4638
Brennan, Rachel C; Qaddoumi, Ibrahim; Billups, Catherine A et al. (2016) Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities. Pediatr Blood Cancer 63:1954-8

Showing the most recent 10 out of 814 publications